Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Macrogenics (MGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 817,500
  • Shares Outstanding, K 48,806
  • Annual Sales, $ 60,120 K
  • Annual Income, $ -171,450 K
  • 60-Month Beta 2.61
  • Price/Sales 13.04
  • Price/Cash Flow N/A
  • Price/Book 2.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.96
  • Number of Estimates 7
  • High Estimate -0.38
  • Low Estimate -1.33
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +6.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.94 +20.01%
on 06/06/19
19.24 -13.05%
on 05/22/19
-1.98 (-10.58%)
since 05/17/19
3-Month
13.94 +20.01%
on 06/06/19
20.13 -16.87%
on 03/26/19
-2.16 (-11.43%)
since 03/19/19
52-Week
9.87 +69.50%
on 02/04/19
32.32 -48.24%
on 02/06/19
-6.22 (-27.10%)
since 06/19/18

Most Recent Stories

More News
Implied Volatility Surging for MacroGenics (MGNX) Stock Options

Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

MGNX : 16.73 (-0.12%)
Macrogenics Inc Shares Down 25.2% Since SmarTrend's Sell Call (MGNX)

SmarTrend identified a Downtrend for Macrogenics Inc (NASDAQ:MGNX) on March 6th, 2019 at $19.60. In approximately 3 months, Macrogenics Inc has returned 25.15% as of today's recent price of $14.67.

MGNX : 16.73 (-0.12%)
MacroGenics to Participate in Jefferies Healthcare Conference

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END

MGNX : 16.73 (-0.12%)
MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced...

MGNX : 16.73 (-0.12%)
Macrogenics Inc has the Best Relative Performance in the Biotechnology Industry (MGNX , MRTX, EPZM , AGIO , FLXN )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

MGNX : 16.73 (-0.12%)
MRTX : 101.23 (-1.04%)
EPZM : 13.25 (+1.53%)
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

-- Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy)

MGNX : 16.73 (-0.12%)
Look for Shares of Macrogenics Inc to Potentially Rebound after Yesterday's 5.63% Sell Off

Macrogenics Inc (NASDAQ:MGNX) traded in a range yesterday that spanned from a low of $15.35 to a high of $16.07. Yesterday, the shares fell 5.6%, which took the trading range below the 3-day low of $16.20...

MGNX : 16.73 (-0.12%)
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -4.21% and -15.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

MGNX : 16.73 (-0.12%)
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided...

MGNX : 16.73 (-0.12%)
MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END

MGNX : 16.73 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade MGNX with:

Business Summary

MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics...

See More

Key Turning Points

2nd Resistance Point 17.31
1st Resistance Point 17.02
Last Price 16.73
1st Support Level 16.50
2nd Support Level 16.28

See More

52-Week High 32.32
Fibonacci 61.8% 23.74
Fibonacci 50% 21.09
Fibonacci 38.2% 18.45
Last Price 16.73
52-Week Low 9.87

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar